Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran
关键词:
摘要:
kowsarpub.com参考文章(16)
Carolyn Day, Paul Haber, Martin Weltman, Maryam Alavi, Annie C Balcomb, Nicky Bath, Gregory Dore, Adrian Dunlop, Jason Grebely, Michelle Micallef, Nghi Phung, Carla Treloar, None, Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. ,vol. 111, pp. 311- 319 ,(2016) , 10.1111/ADD.13197
Federico Salomone, Justyna Godos, Shira Zelber-Sagi, Natural antioxidants for non‐alcoholic fatty liver disease: molecular targets and clinical perspectives Liver International. ,vol. 36, pp. 5- 20 ,(2016) , 10.1111/LIV.12975
Jason Grebely, Elizabeth Knight, Krista A. Genoway, Mark Viljoen, Milan Khara, Doug Elliott, Lesley Gallagher, Michelle Storms, Jesse D. Raffa, Stanley DeVlaming, Fiona Duncan, Brian Conway, Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology. ,vol. 22, pp. 270- 277 ,(2010) , 10.1097/MEG.0B013E32832A8C4C
M. Hickman, T. McDonald, Ali Judd, T. Nichols, V. Hope, S. Skidmore, J. V. Parry, Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial Journal of Viral Hepatitis. ,vol. 15, pp. 250- 254 ,(2008) , 10.1111/J.1365-2893.2007.00937.X
N. Ford, K. Singh, G. S. Cooke, E. J. Mills, T. von Schoen-Angerer, A. Kamarulzaman, P. du Cros, Expanding access to treatment for hepatitis C in resource-limited settings: Lessons from HIV/AIDS Clinical Infectious Diseases. ,vol. 54, pp. 1465- 1472 ,(2012) , 10.1093/CID/CIS227
F. Sahajian, F. Bailly, P. Vanhems, B. Fantino, C. Vannier-Nitenberg, J. Fabry, C. Trepo, , A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. Journal of Public Health. ,vol. 33, pp. 182- 192 ,(2011) , 10.1093/PUBMED/FDQ071
Vincent Leroy, Peter Angus, Jean‐Pierre Bronowicki, Gregory J. Dore, Christophe Hezode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, Maria Jesus Jimenez‐Exposito, Alexander J. Thompson, Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) Hepatology. ,vol. 63, pp. 1430- 1441 ,(2016) , 10.1002/HEP.28473
Fred Poordad, Eugene R. Schiff, John M. Vierling, Charles Landis, Robert J. Fontana, Rong Yang, Fiona McPhee, Eric A. Hughes, Stephanie Noviello, Eugene S. Swenson, Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence Hepatology. ,vol. 63, pp. 1493- 1505 ,(2016) , 10.1002/HEP.28446
James A. D. Freeman, Andrew Hill, The use of generic medications for hepatitis C Liver International. ,vol. 36, pp. 929- 932 ,(2016) , 10.1111/LIV.13157
Behzad Hajarizadeh, Devin Razavi-Shearer, Shahin Merat, Seyed Moayed Alavian, Reza Malekzadeh, Homie Razavi, Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepatitis Monthly. ,vol. 16, ,(2016) , 10.5812/HEPATMON.37234